Article Sidebar

PDF
Date Published: 28/03/2026
Abstract Views: 18
Views PDF: 11
DOI: 10.56535/jmpm.v51i3.1812
Issue
Vol. 51 No. 3 (2026): JOURNAL OF MILITARY PHARMACO-MEDICINE No.3 - 2026
Section
Articles
How to Cite
Ngo, Q. L., Bui, N. H., Vu, M. D., Nguyen, T. D., & Tran, M. S. (2026). CLINICAL CHARACTERISTICS, MICROBIAL ETIOLOGY, AND TREATMENT OUTCOMES OF VENTILATOR-ASSOCIATED PNEUMONIA. Journal of Military Pharmaco-medicine, 51(3), 160-168. https://doi.org/10.56535/jmpm.v51i3.1812

CLINICAL CHARACTERISTICS, MICROBIAL ETIOLOGY, AND TREATMENT OUTCOMES OF VENTILATOR-ASSOCIATED PNEUMONIA

Quy Lam Ngo1, Ngoc Ha Bui1, Minh Duong Vu1, Tien Dung Nguyen1, Minh Son Tran1,
1 Bệnh viện Quân y 103, Học viện Quân y

Main Article Content

Abstract

Objectives: To describe the clinical characteristics, microbiological features, and treatment outcomes of patients diagnosed with ventilator-associated pneumonia (VAP). Methods: A prospective, cross-sectional descriptive study combined with longitudinal follow-up was conducted on 76 patients diagnosed with VAP at the Surgical Intensive Care Unit - Intensive Care and Toxicology Center, Military Hospital 103, from January to June 2025. Results: Among 76 patients, males accounted for 79.0%, with a mean age of 60.97 ± 19.32 years and the age group over 60 accounted for 67.0%. Late-onset VAP (≥ 5 days) was predominant (75.0%). A total of 89 bacterial strains were isolated, Acinetobacter baumannii was the most common pathogen (62.9%). The overall 30-day mortality rate was 42.1%. The mortality rate in the A. baumannii-infected group (51.8%) was statistically significantly higher than in the other groups (15.0%, p < 0.05). Conclusion: Late-onset VAP is prevalent at the study site, with A. baumannii being the primary pathogen and a critical prognostic factor for increased mortality.

Keywords

Clinical characteristics, Treatment outcome, Ventilator-associated pneumonia

Article Details

References

1. Torres A, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal. 2017; 50(3).
2. Papazian L, M Klompas, and CE Luyt. Ventilator-associated pneumonia in adults: A narrative review. Intensive Care Medicine. 2020; 46(5):888-906.
3. Ranzani OT, MS Niederman, and A Torres. Ventilator-associated pneumonia. Intensive Care Medicine. 2022; 48(9): 1222-1226.
4. Najafabadi MK, and R Soltani. Carbapenem-resistant Acinetobacter baumannii and ventilator-associated pneumonia; epidemiology, risk factors, and current therapeutic approaches. Journal of Research in Pharmacy Practice. 2024; 13(2):33-40.
5. Hội Hô hấp Việt Nam, Hội Hồi sức cấp cứu và Chống độc Việt Nam. Khuyến cáo chẩn đoán và điều trị viêm phổi bệnh viện và viêm phổi liên quan thở máy. Nhà xuất bản Y học Hà Nội. 2023.
6. Pape HC, et al. The definition of polytrauma revisited: An international consensus process and proposal of the new “Berlin definition”. Journal of Trauma and Acute Care Surgery. 2014; 77(5):780-786.
7. Li W, et al. Incidence and risk factors of ventilator-associated pneumonia in the intensive care unit: A systematic review and meta-analysis. Journal of Thoracic Disease. 2024; 16(9):5518.
8. Wu D, C Wu, S Zhang, and Y Zhong. Risk factors of ventilator-associated pneumonia in critically III patients. Frontiers in Pharmacology. 2019; 10:482.
9. Kalil AC, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016; 63(5):e61-111.
10. Phu VD, et al. Burden of hospital acquired infections and antimicrobial use in Vietnamese adult intensive care units. PloS One. 2016; 11(1):e0147544.